Nalidixic acid antibodies

Snitkoff et al. [75] reported the development of an EIA for the detection of ciprofloxacin in serum, which was sensitive at picogram per milliliter levels of the antibiotic and no cross-reaction with its metabolites was observed. Gobbo et al. [118] recently described the production of PAb for ciprofloxacin with the aim of detecting fluoroquinolones in Brazilian livestock. On the other hand, Bucknall et al. [77] produced antibodies for quinolones and fluoroquinolones with the aim of developing both generic and specific immunoassays. ELISAs for ciprofloxacin, enrofloxacin, flumequine, and nalidixic acid were developed with sensitivity values around 4 pg kg 1 (on both the generic and specific assays) in bovine milk and ovine kidney. 

Albendazole, ag interferon, anti-CD5 antibody, azathioprine, dimercaprol, hycanthone, interferon, interleukin 2, iron dextran, ivermectin, ketoconazole, lansoprazole, metoprolol, nalidixic acid, OKT3, pefloxacin, tiabendazole, zidovudine... 

Brehm and Korting (1970) had a positive consumption test with cutis extract, but consumption tests with epidermis, vessels, and thymic nuclei were negative. The consumption test by Steffen demonstrates incomplete antibodies. Therefore there is evidence that the bullous nalidixic acid reaction of the skin is an allergic phenomenon with incomplete antibodies against cutis. Routine demonstration of antibodies against nalidixic, pipemidic, and oxolonic acids are not usual. 

Routine lymphocyte transformation tests for nalidixic, pipemidic, and oxolonic acids are not usual, but may be helpful if more than one potential sensitizing medicament has been given. The clinical impression that phototoxic reactions to nalidixic acid are not related to specific antibodies is supported by negative lymphocyte transformation tests (Alexander and Forman 1971). 

Nalidixic, Pipemidic and Oxolonic Acid-Speciflc Antibodies... 

---